OLMA vs. AMRX, RCKT, CPRX, GLPG, AGIO, PTGX, ZLAB, KROS, GPCR, and SNDX
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Amneal Pharmaceuticals (AMRX), Rocket Pharmaceuticals (RCKT), Catalyst Pharmaceuticals (CPRX), Galapagos (GLPG), Agios Pharmaceuticals (AGIO), Protagonist Therapeutics (PTGX), Zai Lab (ZLAB), Keros Therapeutics (KROS), Structure Therapeutics (GPCR), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical preparations" industry.
Amneal Pharmaceuticals (NASDAQ:AMRX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings.
Amneal Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Olema Pharmaceuticals received 15 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Amneal Pharmaceuticals an outperform vote while only 61.54% of users gave Olema Pharmaceuticals an outperform vote.
Amneal Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.
In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 8 mentions for Amneal Pharmaceuticals and 3 mentions for Olema Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.94 beat Olema Pharmaceuticals' score of 0.73 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.
Amneal Pharmaceuticals currently has a consensus target price of $8.25, suggesting a potential upside of 21.50%. Olema Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 137.84%. Given Amneal Pharmaceuticals' higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Amneal Pharmaceuticals.
Olema Pharmaceuticals has a net margin of 0.00% compared to Olema Pharmaceuticals' net margin of -6.76%. Olema Pharmaceuticals' return on equity of 234.06% beat Amneal Pharmaceuticals' return on equity.
31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 17.5% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 19.4% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Olema Pharmaceuticals beats Amneal Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
